

Personal data

Nationality: Italian
Date and place of birth: 30th December 1967, Rome, Italy
Place of living: Milan
Marital status: Married, two children

Education

- 2003 **Ph.D** in Public Health and Policy, London School of Hygiene and Tropical Medicine, University of London, UK.
- 1996 **Master of Science** in Health Services Management *summa cum laude*, London School of Hygiene and Tropical Medicine, University of London, UK.
- 1992 **Laurea Degree** (4-year programme) in Business Administration and Management (110/110) at Università Commerciale Luigi Bocconi, Milan, Italy.

Academic and Institutional Posts

- Since 2017 **Associate Dean** Division Government, Health and Non Profit, Bocconi University School of Management (SDA Bocconi)
- 2012 - 2016 **Director** CERGAS, Centre for Research on Health and Social Care Management, Università Commerciale Luigi Bocconi, Milan, Italy
- Since 2007 **Associate Professor**, Department of Policy Analysis and Public Management at Università Commerciale Luigi Bocconi, Milan, Italy
- 2008 - 2012 **Scientific Director** of the European Health Technology Institute for Socio-Economic Research (EHTI), Brussels, Belgium
- 2008 - 2011 **Director** Master of International Healthcare Management, Economics and Policy (MIHMEP), SDA Bocconi School of Management, Università Commerciale Luigi Bocconi, Milan, Italy

- 2002 - 2007 **Co-Director** Master of International Healthcare Management, Economics and Policy (MIHMEP), SDA Bocconi School of Management, Università Commerciale Luigi Bocconi, Milan, Italy
- 1998 - 2011 **Head** of the Health Technology Assessment (HTA) and Economic Evaluation Analysis of Health Care Programmes Research Unit at CERGAS, Centre for Research on Health and Social Care Management, Università Commerciale Luigi Bocconi, Milan, Italy
- 1999 - 2001 **Coordinator** Master of International Healthcare Management, Economics and Policy (MIHMEP), SDA Bocconi School of Management, Università Commerciale Luigi Bocconi, Milan, Italy
- Since 1993 **Assistant** and then **Professor** at SDA Bocconi School of Management, Università Commerciale Luigi Bocconi, Milan, Italy
- Since 1992 **Researcher** at CERGAS, Centre for Research on Health and Social Care Management, Università Commerciale Luigi Bocconi, Milan, Italy

Teaching

- Since 2017 **Main Instructor** of "Healthcare Management and Policy of Medical devices" – optional course at MIMS (Master of Health Care Management), SDA Bocconi School of Management, Bocconi University, Milan, Italy
- Since 2016 **Main Instructor** of "Public Management (Business Government Relationships)" (taught in English) compulsory course of BSc World Business Bachelor, Bocconi University, Milan, Italy
- Since 2016 **Instructor** of "Health technologies and market access" (taught in English) optional courses for MSc students, Bocconi University, Milan, Italy
- Since 2009 **Main Instructor** of "Health Economics of Medical Devices" – (taught in English) optional course at MIHMEP (Master in International Healthcare Management, Economics and Policy) SDA Bocconi School of Management, Bocconi University, Milan, Italy
- Since 2008 **Main Instructor** of "Economics and Management of Public Administration" – compulsory course for BSc students, Bocconi University, Milan, Italy

- Since 2002** **Main Instructor** of “Economic Evaluation in Health Care” – compulsory course at MIMS (Master of Health Care Management), SDA Bocconi School of Management, Bocconi University, Milan, Italy.
- Since 1999** **Main Instructor** of “Economic Evaluation Analysis of Healthcare Programmes” – (taught in English) compulsory course at MIHMEP (Master in International Healthcare Management, Economics and Policy) SDA Bocconi School of Management, Bocconi University, Milan, Italy
- 2010 - 2014** **Instructor** of “Healthcare Management”, optional course for MSc students, Bocconi University, Milan, Italy
- 2009 - 2010** **Instructor** of “Innovation and Consulting in the Public Sector” – optional course for MSc students, Bocconi University, Milan, Italy
- 2007 - 2009** **Main Instructor** of “Evaluation of Public Programmes” – optional course for MSc students, Bocconi University, Milan, Italy
- 2006 - 2012** **Main Instructor** of “Advanced Economic Evaluation in Health Care” – optional course at MIMS (Master of Health Care Management), SDA Bocconi School of Management, Bocconi University, Milan, Italy
- 2002 - 2005** **Main Instructor** of "Cost Accounting in Healthcare Organisations" (taught in English) compulsory course at MIHMEP (Master in International Healthcare Management, Economics and Policy) SDA Bocconi School of Management, Bocconi University, Milan, Italy.
- 1998 - 2005** **Main Instructor** of “Cost Management in Health Care” - integral course to Methods of Epidemiology, School of Statistics in Health Care, University of Pavia, Italy.
- 2004** **Instructor** of “Economic Evaluation and Clinical Governance” at the Specialised Programme in Clinical Governance, Faculty of Medicine, University La Cattolica, Rome.
- 2003 - 2004** **Main Instructor** of "Healthcare Systems & Management" – optional course (taught in English) for MSc students, Bocconi University, Milan, Italy.
- 1997 - 1999** **Instructor** of “Decision Analysis in Health Care”, Faculty of Pharmacology, La Sapienza University, Rome, Italy.

- 1997 **Coordinator** of Executive Courses in “Health Care Management”, Institute of Health Care, University of Malta, Malta.
- 1996 **Instructor** at the summer course “Economic Evaluation in the Healthcare Sector: an aid to decision-makers?” University of Kuopio, Finland.

Competitive Grants Awarded for Scientific Research

- 2017-20 **Scientific Supervisor** of COMED - *Pushing the boundaries of costs and outcomes analysis of medical technologies*. A 3-year EU HORIZON 2020 - Research and Innovation Framework Programme single-stage grant of 3.017.025,00 Euro. COMED aims at developing new methods and new approaches for the assessment of health technologies within the paradigms of Health Technology Assessment and Health System Performance.
- 2017-20 **Work Package Principal Investigator** of IMPACT HTA - *Improved methods and actionable tools for enhancing Health Technology Assessment*. A 3-year, single-stage, EU HORIZON 2020 - Research and Innovation Framework Programme grant of 4,593,306.00 Euro. The leading institution is the London School of Economics and the consortium is composed by 15 international institutions including eight universities. The general aim of the project is to analyse the determinants of differences in costs and outcomes between major European countries.
- 2013-15 **Work Package Principal Investigator** of MAPPING NCDs - *Mapping Chronic Non-Communicable Diseases Research Activities and their Impact*. A 2-year, two stages, €1.997 million EU Seventh Framework Programme (FP7) grant aimed at mapping European Union member state activity, investment and initiatives to combat NCDs, describing and quantifying their impact in five key disease areas: cardiovascular disease, chronic respiratory diseases, diabetes, cancer and mental health.
- 2013-16 **Partner and Co-Principal Investigator** of “Health and economic outcomes of two different follow up strategies in effectively cured advanced head and neck cancer”. A 3-year, two stages, €100,000 “Swiss Bridge Award” (Switzerland) grant aimed at measuring, comparing and assessing costs and outcomes of two different follow-ups for informing policy decisions on the most cost-effective strategy.
- 2012-15 **Project Leader** of MEDTECHTA – *Methods for Health Technology Assessment of Medical Devices: A European Perspective*. A 3-year, two-stages, €2.055 million EU Seventh Framework Programme (FP7) grant aimed at developing methods to assess medical devices.
- 2011 **Partner** of “Health Governance through Europe”. A 1-year, one-stage, €44,000 EU Lifelong Learning Programme “Leonardo Da Vinci” grant aimed at acquiring best practises in health governance across EU countries.

- 2011-12 **Work Package Coordinator** of “The economic impact of genetic tests on the Italian NHS: identification of clinical pathways, cost-effectiveness and cost-utility analysis and assessment of health policies in Europe”. A 2-year, one-stage, , €380,000 Italian Ministry of Health grant (CCM) aimed at investigating the economic implications of the adoption and diffusion of genetic tests in several disease areas.
- 2010-11 **Coordinator** of “The effect of medical devices on health and retirement”. A 2-year, one-stage, USD 240,000 InHealth (USA) grant aimed at estimating the effect that hip replacement therapy is likely to have on delaying the retirement age of patients with musculoskeletal conditions.
- 2010-12 **Partner and Co-Principal Investigator** of “Cost-utility of conventional haemodialysis vs. short daily haemodialysis for patients coming from automated peritoneal dialysis: a randomised controlled trial”. A 3-year, two-stages, €300,000 Italian Ministry of Health grant (Ricerca Finalizzata) aimed at assessing costs and health outcomes of patients treated by two different haemodialysis strategies.
- 2009-11 **Work Package Principal Investigator** of ECHOUTCOME - *European Consortium in Healthcare Outcomes and Cost-Benefit research*. A 3-year, two-stages, €1.064 million, EU Seventh Framework Programme (FP7) grant aimed at comparing the health system organizations of the 27 Member States and studying the robustness of health outcomes currently used by health technology assessment authorities in Europe.
- 2007-08 **Work Package Principal Investigator** of “Health Technology Assessment of genetic screening: cost-utility analysis of the genetic screening for the predisposition to venous thromboembolism”. A 2-year, one-stage, €109,000, Italian Ministry of Research and University (PRIN) grant aimed at assessing costs and outcomes of genetic screening with a focus on the predisposition to venous thromboembolism in order to advice policy-makers as to the diffusion of genetic screening tests in current medical practice.

Other Appointments

2017	Expert for scientific evaluation of research proposal submitted for grants to the Swiss National Science Foundation. Swiss National Research Council, Switzerland.
Since 2016	Elected Member of the Board of Directors of ISPOR – International Society of Pharmacoeconomics and Outcomes Research
Since 2016	Member of the Board of Directors of Health Trust “Policlinico San Matteo”
2016	Invited Expert by DG Research of the European Commission to the “Research on new methods for improved health economic evaluation workshop” to advice on the preparation of new calls for the EU-Programme Horizon 2020.
Since 2015	Member of the Programme Committee for the Summer School on Health Technology Assessment for Biomedical Engineers and Medical Physicists at the University of Warwick, UK
Since 2015	Member of the Course Committee and Exam Board for the M.Sc. in Health Services Management at Trinity College Dublin, Ireland
Since 2015	Member of “Tavolo Innovazione” [Innovation Table] set up by the Italian Ministry of Health to support the MoH in designing the new reform of HTA in Italy
2015	Expert for the review of research proposals submitted for the grant MR/N015193/1 of MRC (Medical Research Council, UK)
2015-2011	Executive Director of the Economic Affairs at EUCOMED, the European Medical Devices Companies Association.
2014	Expert for the review of research proposals submitted for the call PHC 6 – 2014: Evaluating existing screening and prevention programmes, under the first calls of the research framework programme, Horizon 2020
2013-2015	Member of Vigilance Committee (Organismo di Vigilanza – OdV) of the Health Trust “Istituti di Perfezionamento”, Milan, Italy
2012	Examiner of Mr Matthew Xerri’s PhD thesis “Fostering the innovative behaviour of nursing employees within an Australian context: a social exchange perspective”, Southern Cross School of Business - Southern Cross University, Australia.
2012	Member, Evaluation Committee, Research Grants for Clinical Governance, Emilia-Romagna, Italy

2005 - 2010 Director Economic Affairs Department, Eucomed (European Association of Medical Devices Companies), Brussels, Belgium

Awards

2016 Bocconi university, "Teaching Excellence"
2014 Bocconi University, "Teaching Excellence"
2013 Bocconi University, "Research Excellence"
2013 SDA Bocconi School of Management, Masters' Division "Best Instructor of Specialised Masters"
2012 SDA Bocconi School of Management, "Excellence for Innovation"
2009 SDA Bocconi School of Management, "Excellence for Clients Relations"
1999 Bocconi University, "Research Incentive"

Refereeing

Applied Health Economics and Health Policy, BMJ Open, Critical Reviews in Oncology/Hematology, Expert Review of Medical Devices, Expert Review of Pharmacoeconomics and Outcome Research, European Journal of Health Economics, Health Affairs, Health Policy, International Journal of Technology Assessment in Health Care, Journal of Medical economics, Journal of Medical Marketing, Pharmacoeconomics, Social Science and Medicine, Value in Health.

Affiliations

EHMA – European Health Management Association

iHEA - international Health Economics Association

ISPOR - International Society of Pharmacoeconomics and Outcome Research

HTAi - international Health Technology Assessment Association

Languages

Italian (mother tongue)

English (excellent)

French (basic)

Publications and Books

Articles in International Peer-Reviewed Journals

1. Torbica A, **Tarricone R**, Drummond M. Does the approach to economic evaluation in health care depend on culture, values and institutional context? *European Journal of Health Economics* 2017 <https://doi.org/10.1007/s10198-017-0943-1>.
2. Rognoni C, Ciani O, Sommariva S, **Tarricone R**. Cost-effectiveness analysis of treatments involving radioembolization in intermediate stage hepatocellular carcinoma. *Journal of Comparative Effectiveness Research* 2018;7(3):209-221. doi: 10.2217/ce-2017-0050. Epub 2017 Dec 12.
3. Berger ML, Sox H, Willke RJ, Brixner DL, Eichler H-G, Goettsch W, Madigan D, Makady A, Schneeweiss S, **Tarricone R**, Wang SV, Watkins J, Mullins CD. Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making. *Value in Health* 2017;20:1003-1008.
4. Merzagaglia M, Borsoi L, Cairns J, **Tarricone R**. Mapping health-related quality of life scores from FACT-G, FAACT and FACIT-F onto preference-based EQ-5D-5L utilities in non-small cell lung cancer-cachexia. *European Journal of Health Economics* 2017 doi: 10.1007/s10198-017-0930-6.
5. Begum M, Lewison G, Sommariva S, Ciani O, **Tarricone R**, and Sullivan R. European Diabetes Research And Its Funding, 2002-13. *Diabetic Medicine* 2017 Oct;34(10):1354-1360. doi: 10.1111/dme.13411. Epub 2017 Aug 1.
6. Mujica-Mota R, Watson LK, Tarricone R, Jäger M. Cost-Effectiveness of Timely Versus Delayed Primary Total Hip Replacement In Germany: A Social Health Insurance Perspective. *Orthopedic Reviews* 2017 Oct 2;9(3):7161. doi: 10.4081/or.2017.7161. eCollection 2017 Sep 30.
7. Callea G, Cavallo MC, **Tarricone R**, Torbica A. Learning effect and diffusion of innovative medical devices: the case of transcatheter aortic valve implantation in Italy. *Journal of Comparative Effectiveness Research* 0.2217/ce-2016-0083
8. Rognoni C, **Tarricone R**. Intermittent catheterisation with hydrophilic and non-hydrophilic urinary catheters: systematic literature review and meta-analyses. *BMC Urology* 2017;17(4):1-11.
9. Callea A, Armeni P, Marsilio M, Jommi C, **Tarricone R**. The impact of HTA and procurement practices on the selection and prices of medical devices. *Social Science and Medicine* 2017; 174:89-95.
10. **Tarricone R**, Torbica A, Drummond M. Challenges in the Assessment of Medical Devices: the MedtechHTA project. *Health Economics* 2017;26(Suppl S1):5-12.
11. **Tarricone R**, Callea G, Ogorevc M, Prevolnik Rupel V. Improving the methods for the economic evaluation of medical devices. *Health Economics* 2017;26(Suppl S1):70-92
12. Rothery C, Claxton K, Palmera S, Epstein D, **Tarricone R**, Sculpher M. Characterising uncertainty in the assessment of medical devices and determining future research needs. *Health Economics* 2017;26(Suppl S1):109-123.
13. **Tarricone R**, Torbica A, Drummond M. (for the MedtechHTA project group) Key Recommendations from the MedtechHTA Project. *Health Economics* 2017;26(Suppl S1):145-152.
14. Drummond M, **Tarricone R**, Torbica A, "Incentivising research into the effectiveness of medical devices" *European Journal of Health Economics* 2016; 17:1055-1058.

15. Caselli E, Berloco F, Tognon L, Villone G, La Fauci V, Nola S, Antonioli P, Coccagna M, Balboni PG, Pelissero G, **Tarricone R**, Trua N, Brusaferrò S, Mazzacane S, and Study Group SAN-ICA. Influence of sanitizing methods on healthcare-associated infections onset: a multicentre, randomized, controlled pre-post interventional study. *Journal of Clinical Trials*, 2016 (accepted on October 24th, 2016).
16. Rognoni C and **Tarricone R**. Healthcare Resource Consumption for Intermittent Catheterization: Cost-Effectiveness of Hydrophilic Catheters and Budget Impact Analyses. *BMJ Open* (accepted October 18th, 2016)
17. Rognoni C, Sommariva S, Ciani O, **Tarricone R**, "Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis" *Value in Health* (accepted Sept 12th, 2016)
18. Rognoni C, Ciani O, Sommariva S, Facciorusso A, **Tarricone R**, Bhoori S, Mazzaferro V, "Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses" *Oncotarget* 2016 (accepted July 11th)
19. **Tarricone R**, Boscolo P.R, Armeni P. What type of clinical evidence is needed to assess health technologies? *European Respiratory Review*, 2016;25:259-265.
20. Ciani O, Arendsen E, Romancik M, Lunik R, Costantini E, Di Biase M, Morgia G, Fragalà E, Roman T, Bernat M, Guazzoni G, **Tarricone R**, Lazzeri M. Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulphate (CS) for the treatment of female recurrent urinary tract infections: a European multicenter nested case-control study. *BMJ Open* 2016;6:e009669. doi:10.1136/bmjopen-2015-009669.
21. Armeni P, Boscolo PR, **Tarricone R**, Capodanno D, Maggioni A, Grasso C, Maisano F. Real-World Cost Effectiveness of Mitraclip combined with Medical Therapy Versus Medical Therapy Alone in Patients With Moderate or Severe Mitral Regurgitation. *International Journal of Cardiology* 2016; 209:153-160.
22. Rognoni C, Venturini S, Meregaglia M, Marmifero M, **Tarricone R**, "Efficacy and safety of iron supplementation in anaemic patients: a systematic review and meta-analysis of randomized controlled trials". *Clinical Drug Investigations* 2016; 36(3):177-194
23. **Tarricone R**, Medina Lara A, Abu Koush D. A systematic literature review of the economic implications of chemotherapy-induced diarrhea and its impact on quality of life. *Critical Reviews in Oncology/Hematology* 2016; 99:37-48.
24. **Tarricone R**, Ricca G, Nyanzi-Wakholi B, Medina Lara A. Impact of cancer anorexia-Cachexia Syndrome on Health-Related Quality of Life and Resource Utilisation: a Systematic Review. *Critical Reviews in Oncology/Hematology* 2016; 99:49-62.
25. Sommariva S, Pongiglione B, **Tarricone R**. Impact of Chemotherapy- Induced Nausea and Vomiting on Health-Related Quality of Life and Resource Utilization: a Systematic Review. *Critical Reviews in Oncology/Hematology* 2016;99:13-36.
26. Valzania C, Torbica A, **Tarricone R**, Leyva F, Boriani G. Implant rates of cardiac implantable electrical devices in Europe: a systematic literature review. *Health Policy* 2016;120(1):1-15.
27. Ciani O, Armeni P, Boscolo PR, Cavazza M, Jommi C, **Tarricone R**. De innovatione: the concept of innovation for medical technologies and its implications for healthcare policy-making. *Health Policy & Technology* 2015;5(1):47-64.
28. Generali D, Venturini S, Rognoni C, Ciani R, Pusztai L, Loi S, Jerusalem G, Bottini A, **Tarricone R**. A Network Meta-Analysis of Everolimus plus Exemestane versus Chemotherapy in the First and Second

- Line Treatment of Estrogen Receptor Positive Metastatic Breast Cancer. *Breast Cancer Research and Treatment* 2015;152(1):95-117.
29. Gonzales FM, Finch AP, Armeni P, Boscolo PR, **Tarricone R**. Comparative Effectiveness of Mitraclip versus Optimal Medical Therapy in High-Risk Surgical Patients: a Comprehensive Review. *Expert Review of Medical Devices* 2015;12(4): 471-485.
 30. Beresniak A, Medina-Lara A, Auraye JP, Weverf A, Praetf JC, **Tarricone R**, Torbica A, Dupont D, Lamure M, Durue G. Validation of the underlining assumptions of the QALY outcome: results from the ECHOUTCOME European project. *Pharmacoeconomics* 2015;33(1):61-69.
 31. Gehring M, Jommi C, **Tarricone R**, Cirenei M, Ambrosio G. Towards a More Competitive Italy in Clinical Research: The Survey of Attitudes towards Trial sites in Europe (The SAT-EU StudyTM). *Epidemiology, Biostatistics and Public Health* 2015;12(1):1-9.
 32. Sommariva S, **Tarricone R**, Lazzeri M, Ricciardi W, Montorsi F. Prognostic value of CCP score in patients with prostate cancer: a systematic review and meta-analysis. *European Urology Epub* 2014 Dec 04.
 33. **Tarricone R**, Torbica A, Ferrè F, Drummond M. Generating Appropriate Clinical Data for Value Assessment of Medical Devices: What Role Does Regulation Play? *Expert Review of Pharmacoeconomics and Outcome Research* 2014;14(5):707-718.
 34. Compagni A, Melegaro A, **Tarricone R**. Genetic Screening for the Predisposition to Venous Thromboembolism: A Cost-Utility Analysis of Clinical Practice in the Italian HealthCare System. *Value in Health* 2013; 16: 909-921.
 35. **Tarricone R**. Setting the Scene: The Challenges of Universal Health Coverage and the Contribution of Management Education. *Value in Health* 2013; 16(1 suppl):S4-S6.
 36. Calciolari S, Torbica A, **Tarricone R**. Explaining the health costs associated with managing intracranial aneurysms in Italy. *Applied Health Economics and Health Policy* 2013; 11(4): 427-435.
 37. Ciani O, Grassi D, **Tarricone R**. An economic perspective on urinary tract infection: the "costs of resignation". *Clinical Drug Investigation* 2013; 33(4): 255-261.
 38. Salvatore C, Boscolo PR, **Tarricone R**. Planning and control of medical device investments by Italian public health authorities: A means to improve the decision-making process. *Journal of Medical Marketing* 2013; 13(3): 135-141.
 39. Drummond M, **Tarricone R**, Torbica A. Assessing the added value of health technologies: reconciling different perspectives. *Value in Health* 2013; 16(1 suppl): S7-S13.
 40. Smith BD, **Tarricone R**, Vella V. The role of product life cycle in medical technology innovation. *Journal of Medical Marketing* 2013; 13(1): 37-43.
 41. Callea G, **Tarricone R**, Mujica Mota R. The economic impact of a medical device company's location in Italy. *Journal of Medical Marketing* 2013; 13(1): 24-36.
 42. Mujica-Mota R, **Tarricone R**, Ciani O, Bridges JFP, Drummond M. Determinants of demand for total hip and and knee arthroplasty: a systematic literature review. *BMC Health Services Research* 2012;12:225-257.
 43. Ciani O, **Tarricone R**, Torbica A. Diffusion and use of Health Technology Assessment in policy making: what lessons for decentralised healthcare systems? *Health Policy* 2012; 108(2-3):194-202.
 44. Compagni A, Melegaro A, **Tarricone R**. Systematic review of the economic literature on genetic testing for the prevention of venous thromboembolism. *Italian Journal of Public Health* 2012;9:s36-s45.
 45. Callea G, **Tarricone R**, Medina Lara A. Economic evidence of interventions for acute myocardial infarction: a review of the literature. *Eurointervention* 2012;8:P71-P76.

46. **Tarricone R**, Drummond M. Challenges in the clinical and economic evaluation of medical devices: the case of transcatheter aortic valve implantation. *Journal of Medical Marketing* 2011;11:221-229.
47. Sorenson C, **Tarricone R**, Siebert M, Drummond M. Applying Health Economics for Policy Decision Making: Do Devices Differ From Drugs?. *Europace* 2011;13:ii54-ii58.
48. **Tarricone R**, Torbica A, Franzetti F, Rosenthal VD. Hospital cost of central line-associated bloodstream infections and cost-effectiveness of closed vs. open infusion containers. The case of Intensive Care Units in Italy. *Cost Effectiveness and Resource Allocation* 2010; 1-10.
49. Aguzzi G, Bartoli S, **Tarricone R**. Systematic review of urinary incontinence and overactive bladder cost-of-illness studies. *The Open Pharmacoeconomics & Health Economics Journal* 2010; 11-24.
50. Bartoli S, Aguzzi G, **Tarricone R**. Impact on quality of life of urinary incontinence and overactive bladder: a systematic literature review. *Urology* 2010; 491-500.
51. Drummond M, Griffin A, **Tarricone R**. Economic Evaluation for Devices: Same or Different? *Value in Health* 2009;12(4):402-404.
52. **Tarricone R**, Aguzzi G, Musi F, Fariselli L, Casasco A. Cost-effectiveness for trigeminal neuralgia: Cyberknife vs microvascular decompression. *Neuropsychiatric Disease and Treatment* 2008;4(3):647-652.
53. **Tarricone R**, Aguzzi G, Capone A, Caravaggi CM, Esposito S, Franzetti F, Muzzi A, Ricci L, Bassetti M. How complicated skin and soft tissue infections are treated in Italy: economic evaluation of inpatient intravenous antibiotic treatment in seven hospitals. *Journal of Medical Economics* 2008;11:265-279.
54. **Tarricone R**. Cost-of-Illness analysis – What room in health economics? *Health Policy* 2006;77(1):51-63.
55. Roggero P, **Tarricone R**, Mangiaterra V, Vicoli M. What do people think about disabled youth and employment in developed and developing countries? Results from an e-discussion hosted by the World Bank. *Disability and Society* 2006;21(6):645-650.
56. **Tarricone R**, Girolami F. Economic Evaluation of a New Antiemetic Drug – Palonosetron versus Ondansetron. Assessment of the Drug Price Ratio in Five European countries. *Clinical Drug Investigation* 2005;25(9):597-608.
57. Gerzeli S, **Tarricone R**, Zolo P, Colangelo I, Busca MR, Gandolfo C. The Economic Burden of Stroke in Italy. The eCLIPSE Study: Economic Longitudinal Incidence-based Project for Stroke Evaluation. *Neurological Science* 2005;26:72-80.
58. **Tarricone R**, Marchetti M, Lamotte M, Annemans L, de Jong P. What reimbursement for coronary revascularization with drug-eluting stents? *The European Journal of Health Economics* 2004; 5(4):309-316.
59. Heller B, **Tarricone R**. Oxaprozin versus diclofenac in NSAID-refractory periarthritis pain of the shoulder. *Current Medical Research and Opinion* 2004;20(8):1279-1290.
60. Gillette JA, **Tarricone R**. Economic Evaluation of osteoarthritis treatment in Europe. *Expert Opinion on Pharmacotherapy* 2003; 4(3):327-341.
61. **Tarricone R**, Martelli E, Parazzini F, Darbà J, Le Pen C, Rovira J. Economic Evaluation of Nimesulide Versus Diclofenac in the Treatment of Osteoarthritis in France, Italy and Spain. *Clinical Drug Investigation* 2001; 21(7):453-464.
62. **Tarricone R**, Fattore G, Gerzeli S, Serra G, Taddei C, Percudani M. The costs of pharmacological treatment for major depression. The Italian prospective multi-centre observational incidence-based study. *Pharmacoeconomics* 2000; 17(2): 167-174.

63. **Tarricone R**, Gerzeli S, Montanelli R, Frattura L, Percudani M, Racagni G. Direct and indirect costs of Schizophrenia in community psychiatric services in Italy. The GISIES study. *Health Policy* 2000; 51:1-18.

International Peer-Reviewed Book, Chapters & Encyclopaedia

64. Drummond M, **Tarricone R**, Torbica A. Economic Evaluation of Medical Devices. In Oxford Research Encyclopedia of Economics and Finance edited by J Hamilton, A Dixit, S Edwards, and K Judd, Oxford University Press, 2017 (forthcoming).
65. Drummond M, **Tarricone R**. Public Versus Private Financing. In: (a cura di): Adinolfi Paola;Borgonovo Elio, The myths of health care: towards new models of leadership and management in the healthcare sector. p. 134-137, Springer, 2018, ISBN: 9783319536002.
66. Taylor R, Ciani O, **Tarricone R**. Comparing Drug and Non-Drug Technologies in Comparative Effectiveness Research. In: Comparative effectiveness research, Ed. Adrian Levy, Vol. 1, Handbook of health services research, edited by B. Sobolev. New York: Springer Science + Business Media, 2015.
67. **Tarricone R**, Torbica A. Costing and performance in healthcare management. Faltin, F.W, Kenett, R.S., Ruggeri, F. (edited by) Statistical methods in healthcare. Wiley, UK, 2012, pp.386-404.
68. **Tarricone R**, Tsouros A. Homecare in Europe. The Solid Facts, WHO Regional Office for Europe, 2008.

Articles in Peer-Reviewed Italian Journals

69. Callea G, Cavallo MC, **Tarricone R**, Beccagutti G, Busca R, Corbo M. Il governo dell'innovazione tecnologica in sanità. Il caso dell'impianto di valvola aortica transcateretere: stato dell'arte delle indicazioni e della rimborsabilità nelle regioni italiane. *MECOSAN 2015 (accepted for publication Sept 24th, 2015)*
70. Rognoni C, **Tarricone R**, Meregaglia M, "Impatto economico dell'utilizzo di carbosimaltoso ferrico in pazienti con anemia da carenza di ferro nelle regioni italiane. *MECOSAN 2015*; 93:99-114.
71. Callea G, Torbica A, **Tarricone R**. Impatto del sistema di finanziamento a DRG sull'innovazione tecnologica in sanità. Il caso italiano. *MECOSAN 2014*;89:31-48.
72. **Tarricone R**, Boscolo PR, Ciani O. Valutare l'impatto dell'HTA come strumento di governo dell'innovazione tecnologica: modelli teorici e studi empirici. *Pharmacoeconomics Italian Research Articles 2012*; 14 Suppl. 1: 51-62.
73. Cavallo MC, Ciani O, Gugiatti A, Jommi C, Ruocco G, **Tarricone R**. La gestione dell'innovazione tecnologica in sanità: analisi e confronto di alcune politiche regionali in Italia. *MECOSAN 2012*; 74: 37-65.
74. Armeni P, Ciani O, Tarricone R, Palla I, Pierotti F, Turchetti G. PDTA per la chirurgia bariatrica: l'esperienza di 6 centri italiani. *MECOSAN 2011*;79:9-22.
75. **Tarricone R**, Giaquinto C, LARGERON N, Trichard M. Analisi economica dei costi e dei benefici dell'implementazione di un programma di prevenzione antirotavirus con il vaccino pentavalente in Italia. *Pharmacoeconomics Italian Research Articles 2009*;11(1): 1-13.
76. Torbica A, **Tarricone R**, Calciolari S, Branca V, Gaini SM. Analisi dei costi del trattamento dell'aneurisma intracranico in Italia. *Pharmacoeconomics Italian Research Articles 2009*; 11(1): 25-37.
77. Torbica A, **Tarricone R**, Musi F. Analisi dei costi della procedura angioplastica coronarica per via transradiale in regime ambulatoriale in Italia. *Economia e Politica del Farmaco 2008*;10:37-45.

78. **Tarricone R.** L'analisi di costo sociale delle malattie. Quale ruolo per il management e l'economia sanitaria? *MECOSAN* 2004; 50:49-67.
79. Otto M, Fricke F-U, **Tarricone R.** Analisi costo-efficacia della cura del dolore in Italia: la radioisotopoterapia con Samario-153 e la terapia convenzionale. *MECOSAN* 2004; 52:41-50.
80. **Tarricone R.** L'analisi di costo sociale delle malattie. Quale ruolo per il management e l'economia sanitaria? *MECOSAN* 2004; 50:49-67.
81. Colangelo I, Gerzeli S, **Tarricone R.** I costi ospedalieri dell'ictus in Italia: un confronto tra diversi modelli di cura. *MECOSAN* 2001; 38:27-36.
82. **Tarricone R.** Valutazione di convenienza economica comparata tra quetiapina e risperidone nel trattamento della schizofrenia. *Pharmacoeconomics Italian Research Articles* 2001; 3(1):27-36.
83. Busca MR, Negrini C, Cuccurullo C, **Tarricone R**, Gerzeli S, Gandolfo C, Zolo P. Terapia dell'ictus: valutazione economica e modelli organizzativi. *Argomenti di Neurologia* 2000;10(2):75-79.
84. Inglese L, Graziani L, **Tarricone R.** Il trattamento per cutaneo delle arteriopatie ostruttive periferiche: i perché di una scelta. *Ital Heart J Suppl* 2000;1(19):1138-1147.
85. Costantino MA, **Tarricone R.** Analisi dei costi pieni delle prestazioni di una Unità operativa territoriale di neuropsichiatria dell'infanzia e dell'adolescenza della Lombardia. *Psichiatria dell'infanzia e dell'adolescenza* 1999; 66:361-372.
86. Tabacchi M, **Tarricone R.** Un'analisi di convenienza economica comparata: il trattamento dell'osteoartrite e dell'artrite reumatoide con farmaci antinfiammatori non steroidei. *MECOSAN* 1998;25:53-62.
87. **Tarricone R**, GISIED. Metodologia di indagine e primi risultati sul costo sociale della depressione maggiore in Italia. *MECOSAN* 1997; 22: 57-68.
88. Montanelli R, **Tarricone R.** Il costo sociale della schizofrenia. Una rassegna ragionata della bibliografia. *MECOSAN* 1997; 21:21-31.
89. Mantovani L, Montanelli R, **Tarricone R.** Valutazione economica dell'uso di Gas Plasma di perossido di idrogeno nella sterilizzazione in ambito ospedaliero. *MECOSAN* 1997; 20:34-45.
90. **Tarricone R**, Bertolini F, Grazioli I, Saggioro A. Valutazione economica della prevenzione con misoprostol della gastropatia da farmaci anti-infiammatori non steroidei in Italia. *Argomenti di Gastroenterologia Clinica* 1994;7(7):263-269.
91. **Tarricone R.** Valutare il costo di una malattia. *Prospettive Sociali e Sanitarie* 1994; 19:1-6.
92. **Tarricone R.** Il sistema assicurativo sanitario olandese. *MECOSAN*, 1994; 10: 98-110.
93. **Tarricone R.** I costi sanitari dell'ischemia critica cronica degli arti. *Bollettino SIFO*, 1993; 39 (4): 281-288.
94. **Tarricone R**, Borgonovi E. Stima dei costi sanitari dell'ischemia critica cronica degli arti. *Annali Italiani di Medicina Interna*, 1993; 8(suppl): 81-84.
95. **Tarricone R.** Aspetti critici del sistema di riordino del Servizio Sanitario Nazionale. *MECOSAN*, 1992; 3: 150-151.

Italian Books and Chapters

96. Ciani O, **Tarricone R**, Torbica A. Programma nazionale HTA per dispositivi medici: quali sfide per l'implementazione? In AA.VV. Rapporto OASI 2015. L'aziendalizzazione della sanità in Italia, EGEA, Milano, 2016, pagg. 615-634.

97. Boscolo PR, Ciani O, **Tarricone R**, Torbica A. La funzione di HTA nelle aziende sanitarie italiane: un potenziale ancora inutilizzato? In AA.VV. Rapporto OASI 2015. L'aziendalizzazione della sanità in Italia, EGEA, Milano, 2015, pagg. 583-605
98. Armeni P, Callea G, **Tarricone R**. L'adozione dell'innovazione tecnologica da parte degli ospedali italiani: un'analisi dei fattori endogeni. In AA.VV. Rapporto OASI 2014. L'aziendalizzazione della sanità in Italia, EGEA, Milano, 2014, pagg. 381-400.
99. **Tarricone R**, Valotti G. Il miglioramento del performance management nelle aziende sanitarie pubbliche: oltre le mode e le tradizioni. In AA.VV "Strategia e Performance management nelle Aziende Sanitarie Pubbliche", EGEA, 2013.
100. Carbone C, Lecci F, Lega F, Prenestini A, Rotolo A, **Tarricone R**, Valotti G. Misurare le performance per creare valore nelle aziende sanitarie pubbliche: uno strumento multidimensionale di valutazione. In AA.VV. Rapporto OASI 2013. L'aziendalizzazione della sanità in Italia, EGEA, Milano, 2013, pagg. 515-550.
101. **Tarricone R** (edited by). Politiche per la salute e scelte aziendali. Impatto sull'innovazione e diffusione delle tecnologie mediche. EGEA, 2012.
102. **Tarricone R**. Innovazione e Competitività nei Sistemi Industriali Regolati. Le Imprese di Dispositivi Medici. EGEA, Milano, 2010.
103. Fattore G, Cavallo MC, **Tarricone R**. Lo sviluppo dell'Health Technology Assessment in Italia: contenuti, approcci e riferimenti internazionali. In Anessi Pessina E, Cantù E. Rapporto OASI 2008. L'aziendalizzazione della Sanità in Italia, EGEA, Milano, 2008, pagg. 151-178
104. **Tarricone R**. Valutazioni economiche e management in sanità: applicazioni ai programmi e tecnologie sanitarie. McGraw-Hill, Milano, 2004.

Papers Presented at Scientific Congresses

1. **Tarricone R**. "mHealth among clinicians and patients in cancer care: How to address the digital divide?". Issue Panel AT XX Annual Conference of ISPOR (International Society of Health Economics and Outcomes Research), 6th – 8th, Glasgow (UK), 2017.
2. **Tarricone R**. HTA Methods For Medical Technologies: Development, Applications, And Future Advancements. HTAi Annual Meeting, Rome, 19th – 21st June.
3. **Tarricone R**. HTA of Medical Devices: Are We Getting Closer To Solve The Puzzle? HTAi Annual Meeting, Rome, 19th – 21st June.
4. **Tarricone R**. Sanità e nuove tecnologie. "La Salute diseguale", Festival dell'Economia, Trento, 1st-4th June 2017.
5. **Tarricone R**. Use of Real-world Evidence to Shape Health Policies for Medical Devices. ISPOR, 22nd Annual International Meeting, Boston (USA), 22nd – 24th May 2017.
6. **Tarricone R**. Incentivizing Research into the Effectiveness of Medical Devices. ISPOR 19th Annual European Congress, Vienna, 9th October – 2nd November 2016.

7. **Tarricone R.** New Challenges For High-Risk Medical Devices In Europe. How To Achieve The Balance Between The Demand For Early Product Launch And Safety? ISPOR 19th Annual European Congress, Vienna, 9th October – 2nd November 2016.
8. **Tarricone R.** The digital divide between clinicians and patients. Results from an international e-survey on mHealth in cancer supportive care. MASCC Annual Meeting on Supportive Care in Cancer, Adelaide, Australia, June 23th – 25th, 2016.
9. **Tarricone R.** Regulation and Market Access for Medical Devices. XIV Mediterranean Conference on Medical and Biological Engineering and Computing, Paphos, Cyprus, March 31st – April 2nd, 2016.
10. **Tarricone R.** HTA of drugs and medical devices: same or different? XIV Mediterranean Conference on Medical and Biological Engineering and Computing, Paphos, Cyprus, March 31st – April 2nd, 2016.
11. **Tarricone R.** Advancing methods of Health Technology Assessment for medical devices: an introduction to the EU MedTechHTA project. Invited speech at 10th Forum HAS (Haute Autorité de Santé), Paris, France, 30th October, 2015.
12. **Tarricone R.** Advancing methods of Health Technology Assessment for medical devices: key recommendations from the EU MedTechHTA project. International Health Economics Association, 11th World Congress, Milan, Italy, 12th-15th July, 2015.
13. **Tarricone R.** Cost-of-Illness Analysis. Invited key note speech at ISPOR Israel Chapter, Tel Aviv, Israel, 10th April, 2014.
14. **Ciani C, Lazzeri M, Tarricone R.** Retrospective analysis of laluril vs Standard of Care in Recurrent Urinary Tract Infections: RAISC-RUTI study protocol and preliminary results. 29th Annual EAU Congress, Stockholm, Sweden, 12th April 2014.
15. **Tarricone R.** Does assessing the value for money of medical devices require a flexible approach? ISPOR Dublin, UK, 4th-6th November, 2013.
16. **Tarricone R.** Health Technology Assessment: Opportunities and Limitations. EHF Gastein, Austria, 1st-3rd October, 2013.
17. **Tarricone R, Armeni P, Boscolo PR, Callea G, Cavazza M, Ciani O, Jommi C, Marsilio M, Torbica A.** Do HTA practices and procurement policies impact expenditures for medical devices? EHMA Milan, Italy, 26th-28th June, 2013.
18. **Mujica Mota RE, Tarricone R, Bridges J, Drummond M.** Demand for total hip and knee replacement and retirement decisions in Europe. European Conference on Health Economics, Zurich, Switzerland, 18th-21st July, 2012.
19. **Compagni A, Melegaro A, Tarricone R, Villari P, Di Maria E, Ricciardi G.** A Real World Cost-Effectiveness Analysis of the Genetic Screening for Predisposition to Venous Thromboembolism (VTE) in the Italian Context. International Congress on Health Economics, Toronto, Canada, 9th-13th July, 2011.
20. **Tarricone R.** Le Tecnologie Mediche nel SSN. Volumi, Spesa e Processi di Acquisto. III Conferenza Nazionale sui Dispositivi Medici del Ministero della Salute. Rome, Italy, 13th-14th April, 2010.
21. **Tarricone R.** Treatment Innovations for Osteoarthritis: a budget impact analysis of chondroitin sulphate and NSAIDs. EULAR (European League against Rheumatism). Copenhagen, Denmark, 11th June, 2009.

22. **Tarricone R.** La ricerca nell'HTA. Quali le questioni aperte? 8° Convegno Nazionale di Economia del Farmaco e delle Tecnologie Sanitarie. Università Cattolica, Milano, Italy, 21st May, 2009.
23. **Tarricone R.** How to improve user access to innovative medical devices: what is needed? 5th Annual HTAi Meeting, Montreal, Canada, 6th-9th July, 2008.
24. **Tarricone R.** Are Medical Devices more challenging to evaluate than Drugs? 10th ISPOR European Conference, Dublin, Ireland, 20th-23rd October, 2007.
25. **Tarricone R,** Torbica A. "Economic Evaluation Analysis and HTA". 2° Forum sulle Tecnologie, Trento, Italy, 27th January, 2007.
26. **Tarricone R.** "Il contributo delle valutazioni economiche alla sostenibilità dei sistemi sanitari". 5° Congresso Nazionale di Farmacoeconomia, Università Bocconi, Milan, Italy, 13th-14th June, 2006.
27. **Tarricone R.** "Efficienza ed Efficacia in Sanità". Oltre le Nuove Tecnologie, Napoli, Italy, 21st-22nd April, 2005.
28. Roggero P, **Tarricone R.** "Employment and Youth with Disability: sharing knowledge and practice". Employment and Disability, World Bank, Washington DC, 30th-1st December, 2004.
29. **Tarricone R,** Marchetti M. Cost-Effectiveness Analysis of Cypher. 2nd International Congress on Clinical and Interventional Cardiology, Taormina, Italy, 25th-29th May, 2002.
30. **Tarricone R,** Colangelo I, Gerzeli S, Busca R. "Direct costs of stroke in Italy". iHEA Conference, York, UK, 21st-26th July, 2001.
31. **Tarricone R.** "Valutazione economica comparata tra Quetiapina e Risperidone nel trattamento della schizofrenia". Convegno Nazionale della Società Italiana di Farmacologia, Genova 31st-2nd June, 2001.
32. **Tarricone R,** Gerzeli S, Montanelli R. "Direct costs of Schizophrenia". Third International Congress on Health Economics, Evora, Portugal, 15th-17th October, 1997.
33. **Tarricone R,** Fattore G. "The economic burden of Major Depression". International Health Economics Association Inaugural Conference, Vancouver, Canada, 19th-23rd May, 1996.
34. **Tarricone R,** De Benedetti A. "A comparative study on costs incurred in delivering endoscopy services to patients with IBD and those with other gastroenteric pathologies". VRO Conference, Venice, 26th May 1994.